Holen Sie sich die Stockscreener-App
9.21
1.92%
-0.18
Handel nachbörslich:
9.25
0.04
+0.43%
Schlusskurs vom Vortag:
$9.39
Offen:
$9.5
24-Stunden-Volumen:
5.53M
Relative Volume:
2.37
Marktkapitalisierung:
$1.91B
Einnahmen:
$331.41M
Nettoeinkommen (Verlust:
$-226.54M
KGV:
-7.8051
EPS:
-1.18
Netto-Cashflow:
$-97.31M
1W Leistung:
+1.77%
1M Leistung:
+21.02%
6M Leistung:
+14.98%
1J Leistung:
+63.01%
1-Tages-Spanne:
$9.155
$9.50
1-Wochen-Bereich:
$9.09
$9.50
52-Wochen-Spanne:
$4.03
$9.50
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Branche
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Vergleichen Sie BCRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.21 | 1.91B | 331.41M | -226.54M | -97.31M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BIOCRYST PHARMACEUTICALS Earnings Preview: Recent $BCRX Insider Trading, Hedge Fund Activity, and More - Nasdaq
BioCryst Pharmaceuticals (BCRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
T-cell Lymphoma Market Generated Opportunities, Future Scope - openPR
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Savant Capital LLC Decreases Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire
BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month HighStill a Buy? - MarketBeat
BioCryst to Present at Upcoming Investor Conferences - GlobeNewswire Inc.
Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Price Target at $15.50 - MarketBeat
BioCryst stock soars to 52-week high, touches $9.02 - MSN
JMP Securities maintains BioCryst stock with $18 target By Investing.com - Investing.com Canada
BioCryst up 8% after raising 2024 Orladeyo revenue guidance - MSN
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 12-Month HighTime to Buy? - MarketBeat
BioCryst Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Fly 25% But Investors Aren't Buying For Growth - Simply Wall St
BioCryst stock soars to 52-week high, touches $9.02 By Investing.com - Investing.com South Africa
Oral HAE treatment Orladeyo now available to patients in Portugal - Angioedema News Today
Portugal approves daily oral therapy for hereditary angioedema By Investing.com - Investing.com Nigeria
Portugal approves daily oral therapy for hereditary angioedema - MSN
BioCryst Says Orladeyo Recommended for Hereditary Angioedema Prevention in Portugal - Marketscreener.com
BioCryst Launches ORLADEYO® (berotralstat) in Portugal - The Manila Times
Breakthrough: Portugal Gets First-Ever Daily Oral HAE Treatment as ORLADEYO Expands Global Reach - StockTitan
Ebola Virus Vaccine Market May See a Big Move| Arbutus Biopharma, BioCryst Pharmaceuticals - openPR
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24 - GlobeNewswire
Where are the Opportunities in (BCRX) - Stock Traders Daily
BioCryst to Present New ORLADEYO® (berotralstat) Results - GlobeNewswire
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress - The Manila Times
BCRX Unveils Groundbreaking Pediatric Trial Data: ORLADEYO Shows Promise in Children Under 12 - StockTitan
BioCryst (BCRX) Q4 Earnings Call: Key Financial Updates Coming February 24Here's What to Track - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month HighShould You Buy? - MarketBeat
BioCryst Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Up 9.1%Still a Buy? - MarketBeat
SG Americas Securities LLC Sells 117,571 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX) - Defense World
SG Americas Securities LLC Has $311,000 Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Large Decrease in Short Interest - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inside BioCryst's Latest Executive Compensation Move: Key Details on New Hire Stock Grants - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Market Outperform" Rating at JMP Securities - MarketBeat
CPRX: 3 Niche Healthcare Stocks Tackling Rare Diseases - StockNews.com
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.27%
3.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):